EP1589996A4 - Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees - Google Patents
Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associeesInfo
- Publication number
- EP1589996A4 EP1589996A4 EP04707034A EP04707034A EP1589996A4 EP 1589996 A4 EP1589996 A4 EP 1589996A4 EP 04707034 A EP04707034 A EP 04707034A EP 04707034 A EP04707034 A EP 04707034A EP 1589996 A4 EP1589996 A4 EP 1589996A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- integrin alpha
- alpha beta
- formulat ions
- formulat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44377703P | 2003-01-30 | 2003-01-30 | |
US44381003P | 2003-01-30 | 2003-01-30 | |
US443777P | 2003-01-30 | ||
US443810P | 2003-01-30 | ||
PCT/US2004/002701 WO2004066957A2 (fr) | 2003-01-30 | 2004-01-30 | Preparation d'anticorps anti-integrine $g(a)v$g(b)3 et utilisations associees |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1589996A2 EP1589996A2 (fr) | 2005-11-02 |
EP1589996A4 true EP1589996A4 (fr) | 2009-01-21 |
Family
ID=32829839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04707034A Withdrawn EP1589996A4 (fr) | 2003-01-30 | 2004-01-30 | Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1589996A4 (fr) |
JP (1) | JP2006516636A (fr) |
AU (1) | AU2004207003A1 (fr) |
CA (1) | CA2512174A1 (fr) |
WO (1) | WO2004066957A2 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973134B2 (en) | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
US20060046961A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
US7935790B2 (en) | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7807789B2 (en) | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
AU2006278573A1 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
EP1934867A2 (fr) | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reactifs de detection de phosphorylation proteinique dans des voies de signalisation de leucemie |
SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
US7939636B2 (en) | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
US9388235B2 (en) | 2006-09-05 | 2016-07-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
EP2094247B1 (fr) | 2006-10-20 | 2022-06-29 | Amgen Inc. | Formulations stables de polypeptide |
US20090081659A1 (en) | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1975184A3 (fr) | 2007-03-26 | 2008-11-26 | Cell Signaling Technology, Inc. | Sites de phosphorylation à sérine ou thréonine |
CN101679507A (zh) | 2007-03-29 | 2010-03-24 | 艾博特公司 | 结晶抗人类il-12抗体 |
EP1983002A3 (fr) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Sites de phosphorylation à tyrosine et anticorps spécifiques |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP1983003A3 (fr) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Sites de phosphorylation à tyrosine et anticorps spécifiques |
US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
MY151252A (en) * | 2007-10-09 | 2014-04-30 | Hercules Inc | Crosslinker-containing adhesive compositions |
US20090203043A1 (en) | 2007-11-21 | 2009-08-13 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
CA2794631A1 (fr) * | 2010-03-31 | 2011-10-06 | Universite De Geneve | Preparations d'anticorps stabilises et utilisations correspondantes |
US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
JP6345123B2 (ja) | 2012-02-16 | 2018-06-20 | サンタラス, インコーポレイテッド | 抗vla1(cd49a)抗体医薬組成物 |
CN114569716A (zh) | 2014-10-23 | 2022-06-03 | 美国安进公司 | 降低药物制剂的粘度 |
TWI728118B (zh) | 2016-06-02 | 2021-05-21 | 美商艾伯維有限公司 | 糖皮質素受體促效劑及其免疫結合物 |
JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
RU2020117698A (ru) | 2017-12-01 | 2022-01-04 | Эббви Инк. | Агонист глюкокортикоидного рецептора и его иммуноконъюгаты |
WO2020060183A1 (fr) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | Formation de liquide pour stabiliser un anticorps de trastuzumab |
WO2020141608A1 (fr) * | 2019-01-04 | 2020-07-09 | 国立大学法人京都大学 | Méthode de test pour la rectocolite hémorragique et la cholangite sclérosante primitive |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010016645A1 (en) * | 1997-01-30 | 2001-08-23 | Ixsys, Incorporated | Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use |
WO2002013860A1 (fr) * | 2000-08-11 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees contenant un anticorps |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
-
2004
- 2004-01-30 WO PCT/US2004/002701 patent/WO2004066957A2/fr active Application Filing
- 2004-01-30 EP EP04707034A patent/EP1589996A4/fr not_active Withdrawn
- 2004-01-30 AU AU2004207003A patent/AU2004207003A1/en not_active Abandoned
- 2004-01-30 JP JP2006503199A patent/JP2006516636A/ja not_active Withdrawn
- 2004-01-30 CA CA002512174A patent/CA2512174A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010016645A1 (en) * | 1997-01-30 | 2001-08-23 | Ixsys, Incorporated | Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use |
WO2002013860A1 (fr) * | 2000-08-11 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees contenant un anticorps |
EP1314437A1 (fr) * | 2000-08-11 | 2003-05-28 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees contenant un anticorps |
Also Published As
Publication number | Publication date |
---|---|
CA2512174A1 (fr) | 2004-08-12 |
AU2004207003A1 (en) | 2004-08-12 |
WO2004066957A3 (fr) | 2005-04-07 |
WO2004066957A2 (fr) | 2004-08-12 |
EP1589996A2 (fr) | 2005-11-02 |
JP2006516636A (ja) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1589996A4 (fr) | Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees | |
IL174637A0 (en) | Fibrosis-inducing agents, compositions containing the same and medical implants containing the same | |
PT1736541E (pt) | Nova proteína galectina 9 modificada e sua utilização | |
AU2003295402A8 (en) | Acyl guanidine compounds and use thereof | |
EP1767634A4 (fr) | Nouvelle proteine de modification galectine 8 et utilisation de celle-ci | |
GB0220214D0 (en) | Compounds and their use | |
AU2003296369A8 (en) | Imminoamines and preparation thereof | |
AU2003215257A8 (en) | Modified defensins and their use | |
EP1589033A4 (fr) | Anticorps et utilisation de ce dernier | |
HK1209049A1 (en) | Survivin-derived peptides and use thereof | |
EP1582586A4 (fr) | Proteine associee a l'apoptose et son utilisation | |
AU2003275123A8 (en) | Composition containing ribavirin and use thereof | |
GB0227906D0 (en) | Compounds and their use | |
EP1541677A4 (fr) | Nouvelles proteines et leur utilisation | |
EP1577322A4 (fr) | Nouvelles proteines et leur utilisation | |
GB0230134D0 (en) | Compounds and their use | |
EP1627888A4 (fr) | Anticorps et son utilisation | |
GB0230281D0 (en) | Compounds and their use | |
GB0218031D0 (en) | Compounds and their use | |
FR2859108B1 (fr) | Composition anti-stress et son inhalateur | |
GB0321300D0 (en) | Protein structure and uses thereof | |
GB0220215D0 (en) | Compounds and their use | |
GB0228538D0 (en) | Protein structure and uses thereof | |
GB0311164D0 (en) | Composition and use | |
GB0311167D0 (en) | Composition and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050816 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20081219 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090318 |